Lenvatinib Mesylate CAS 857890-39-2 Assay 98.0~102.0% Factory

Lenvatinib Mesylate (CAS: 857890-39-2) ke inhibitor ea molomo le e mengata ea VEGFR1-3, FGFR1-4, PDGFR, KIT, le RET, e nang le mesebetsi e matla ea antitumor.Lenvatinib Mesylate ke receptor tyrosine kinase (RTK) inhibitor e nang le khetho bakeng sa VEGFR2.E bonts'a ts'ebetso ea li-antineoplastic, 'me e bontšitsoe bakeng sa phekolo ea bakuli ba nang le kankere ea qoqotho e fapaneng kapa ea metastatic, e tsoelang pele, e nang le mahlaseli a kotsi (RAI) -refractory differentiated.Lenvatinib Mesylate e ile ea amoheloa ka lekhetlo la pele ke Tsamaiso ea Lijo le Lithethefatsi ea US (FDA) ka Feb 13, 2015, eaba e amoheloa ke Pharmaceuticals and Medical Devices Agency of Japan (PMDA) ka Mar 26, 2015, 'me ea amoheloa ke European Medicine Agency (EMA) ka. May 28, 2015. E ile ea ntlafatsoa le ho rekisoa e le Lenvima® ke Eisai.Lenvatinib Mesylate ke oral multiple receptor tyrosine kinase inhibitor e nang le mokhoa o ikhethileng oa ho tlama o thibelang ka mokhoa o ikhethileng mesebetsi ea kinase ea li-vascular endothelial growth factor (VEGF) receptors, ho phaella ho tse ling tsa proangiogenic le oncogenic tse amanang le tsela ea tyrosine kinases eo ho nahanoang hore e ameha ho ata ha hlahala. .E bontšoa bakeng sa phekolo ea kankere ea qoqotho e tsoelang pele ea radioiodine-refractory.Lenvimae sebelisoa ka boeona ho alafa differentiated thyroid cancer (DTC), mofuta oa kankere ea qoqotho e ke keng ea hlola e phekoloa ka iodine ea mahlaseli ’me e ntse e tsoela pele.LENVIMA e sebelisoa hammoho le moriana o mong o bitsoang everolimus ho phekola batho ba baholo ba nang le mofuta oa mofetše oa liphio o bitsoang advanced renal cell carcinoma (RCC) ka mor'a mokhoa o mong oa kalafo ka moriana o mong o thibelang mofetše.